How to use atezolizumab subcutaneous formulation (TECENTRIQ HYBREZA)

Atezolizumab subcutaneous preparation is a programmed death -ligand 1 (PD-L1) blocking antibody, combined with endoglycosidase to form a compound formula, used for the treatment of a variety of malignant tumors, including non-small cell lung cancer, small cell lung cancer, hepatocellular carcinoma, melanoma and alveolar soft tissue sarcoma. This formulation is an optimized choice of formulation form for atezolizumab, aiming to provide a more convenient dosing experience while retaining its pharmacological activity as an immune checkpoint inhibitor.

The recommended dose of this drug is to be injected once every three weeks, 15 ml each timeThe injection time is about 7 minutes, and it should be performed by trained professional medical personnel. The site of subcutaneous injection should be selected in the thigh muscle area and ensure that the skin is intact and undamaged. When using, avoid injecting the drug into areas where the skin is red, itchy, indurated, damaged or tender to reduce the risk of local irritation. Clinically, it is recommended to inject alternately between the left and right thighs, and the location of each injection should be at least 2.5 cm away from the previous one to avoid repeated pressure on local tissues or drug residue.

The subcutaneous formulation of atezolizumab is different from traditional intravenous infusion in that its administration route is limited to subcutaneous injection and cannot be used for intravenous access. The hyaluronidase component specifically included in its preparation can improve the distribution of large-volume medicinal solutions in subcutaneous tissues, helping to improve the absorption rate and local tolerance of the drug. Therefore, it must be administered strictly by the subcutaneous injection route and cannot be substituted for other administration methods.

Before and after administration, professional medical staff need to assess the patient's clinical status, including the skin condition at the injection site, monitoring of systemic adverse reactions, and recording tolerance after the previous medication. In order to avoid adverse reactions or local interference caused by mixing with other subcutaneous injection drugs, avoid giving other drugs at the same injection area at the same time. If it is necessary to combine other subcutaneous injection drugs, it should be used in a site other than the thigh.

The use of atezolizumab subcutaneous preparations is not suitable for patient self-operation and must be managed by medical institutions in an environment with necessary conditions and emergency support to ensure that patients can receive immediate intervention if they experience any discomfort during treatment. The treatment cycle and duration need to be individually adjusted by a specialist based on the patient's condition, tolerance and clinical response.

Reference materials:https://www.drugs.com/search.php?searchterm=TECENTRIQ+HYBREZA